aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Talus Bio: Innovating drug development for gene regulation with cutting-edge technology.
Founded to revolutionize drug discovery, Talus Bio focuses on targeting the DNA regulome—previously considered undruggable genome regulators. The company has developed a pioneering platform that shifts drug discovery from artificial systems to live human cells, ensuring accurate functionality of regulome proteins. Their technology integrates automated cell processing, next-gen proteomics, and advanced data analytics to assess a drug's impact on the entire regulome in a single experiment. Talus Bio aims to transform the pharmaceutical landscape by making previously inaccessible targets viable for therapeutic intervention.
Notable figures associated with Talus Bio include Dr. Lindsay Pino, who is featured in "The Proteomics Show." The company has garnered significant attention and support, evidenced by the successful close of a seed funding round and the hiring of a new COO. Talus Bio's achievements include securing new grants to expedite the development of transcription factor drugs. By advancing the understanding and manipulation of gene regulation, Talus Bio is poised to make a substantial impact on the field of drug development and personalized medicine.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Drug Discovery
Technology
Biotech
Tags
Data
Model Types
Platform
Revenue Type(s)
Consulting
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was Talus Bio founded?
Talus Bio was founded in 2020.
Where is Talus Bio’s headquarters located?
Talus Bio’s headquarters is located in BR.
When was Talus Bio’s last funding round?
Talus Bio’s most recent funding round was for $4.3M (USD) in August 2023.
How many employees does Talus Bio have?
Talus Bio has 40 employees as of Feb 24, 2024.
How much has Talus Bio raised to-date?
As of July 05, 2023, Talus Bio has raised a total of $14.3M (USD) since Aug 18, 2023.
Add Comparison
Total Raised to Date
$14.3M
USD
Last Update Aug 18, 2023
Last Deal Details
$4.3M
USD
Aug 18, 2023
Grant
Total Employees Over Time
40
As of Feb 2024
Talus Bio Address
Brazil
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts